fenofibrate has been researched along with Cutaneous T-Cell Lymphoma in 4 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bexarotene is an oral retinoid approved for treating cutaneous T-cell lymphoma (CTCL) in patients resistant to first-line systemic treatment." | 7.85 | Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. ( Bardés, I; Cabello, I; Corbella, X; Pintó, X; Servitje, O, 2017) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 5.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| "Bexarotene is an oral retinoid approved for treating cutaneous T-cell lymphoma (CTCL) in patients resistant to first-line systemic treatment." | 3.85 | Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. ( Bardés, I; Cabello, I; Corbella, X; Pintó, X; Servitje, O, 2017) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 1.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cabello, I | 1 |
| Servitje, O | 1 |
| Corbella, X | 1 |
| Bardés, I | 1 |
| Pintó, X | 1 |
| Musolino, A | 1 |
| Panebianco, M | 1 |
| Zendri, E | 1 |
| Santini, M | 1 |
| Di Nuzzo, S | 1 |
| Ardizzoni, A | 1 |
| Scarisbrick, JJ | 1 |
| Morris, S | 1 |
| Azurdia, R | 1 |
| Illidge, T | 1 |
| Parry, E | 1 |
| Graham-Brown, R | 1 |
| Cowan, R | 1 |
| Gallop-Evans, E | 1 |
| Wachsmuth, R | 1 |
| Eagle, M | 1 |
| Wierzbicki, AS | 1 |
| Soran, H | 1 |
| Whittaker, S | 1 |
| Wain, EM | 1 |
| Martin, PG | 1 |
| Lasserre, F | 1 |
| Calleja, C | 1 |
| Van Es, A | 1 |
| Roulet, A | 1 |
| Concordet, D | 1 |
| Cantiello, M | 1 |
| Barnouin, R | 1 |
| Gauthier, B | 1 |
| Pineau, T | 1 |
4 other studies available for fenofibrate and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Chemotherapy, Adjuvant; Drug Th | 2017 |
Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
Topics: Adult; Aged; Bexarotene; Contraindications; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; | 2009 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, | 2013 |
Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks.
Topics: Animals; Apolipoproteins; Bexarotene; Blotting, Northern; Cell Nucleus; Cluster Analysis; Dimerizati | 2005 |